Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert Ossenkoppele

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Blood Advances|July 8, 2018
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemiaAnne-Sophie Bouillon, Monica S Ventura Ferreira, Shady Adnan Awad, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.
Leukemia|July 1, 2020
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemiaMarkus Pfirrmann, Richard E Clark, Witold Prejzner, et al.
Blood|November 8, 2008
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparisonJan J Cornelissen, Bronno van der Holt, Gregor E G Verhoef, et al.
Haematologica|May 20, 2017
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinibStein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free RemissionFrancois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, et al.
JCO Precision Oncology|February 17, 2022
Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete RemissionJurjen Versluis, Burak Kalin, Wendelien Zeijlemaker, et al.
Blood Advances|February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetAdriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Blood Advances|July 8, 2018
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemiaAnne-Sophie Bouillon, Monica S Ventura Ferreira, Shady Adnan Awad, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Blood|August 12, 2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsHartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, et al.
Leukemia|July 1, 2020
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemiaMarkus Pfirrmann, Richard E Clark, Witold Prejzner, et al.
Blood|November 8, 2008
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparisonJan J Cornelissen, Bronno van der Holt, Gregor E G Verhoef, et al.
Haematologica|May 20, 2017
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinibStein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free RemissionFrancois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, et al.
JCO Precision Oncology|February 17, 2022
Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete RemissionJurjen Versluis, Burak Kalin, Wendelien Zeijlemaker, et al.
Blood Advances|February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetAdriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Pageof 6